A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
The primary objective of the study is to evaluate the pharmacokinetic (PK) comparability of 2 fixed subcutaneous (SC) doses of aducanumab with a single, weight-based intravenous (IV) dose of aducanumab in healthy volunteers. The secondary objectives of the study are to assess the safety and tolerability of aducanumab administered SC in healthy volunteers and to characterize additional PK parameters of 2 fixed SC doses of aducanumab and a single, weight-based IV dose of aducanumab.

Official Title
-----------------
A Randomized, Open-Label, Parallel-Arm Study to Assess the Pharmacokinetic Comparability of 2 Fixed Subcutaneous Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous Dose in Healthy Volunteers

Conditions
-----------------
Healthy Volunteer

Intervention / Treatment
-----------------
* Biological: Aducanumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Have a body mass index between 18 and 30 kilograms per meter square (kg/m^2), inclusive Japanese participant has both biological parents and all 4 grandparents of Japanese descent Have a negative polymerase chain reaction test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on Day -1 Key Exclusion Criteria: History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator History of severe allergic, anaphylactic or systemic hypersensitivity reactions, or of any allergic reactions that in the opinion of the Investigator are likely to be exacerbated by aducanumab, the excipients contained in the formulation, and if appropriate, any diagnostic agents to be administered during the study History of, or positive test result at Screening for, human immunodeficiency virus History of hepatitis C infection or positive test result at Screening for hepatitis C virus antibody Symptoms consistent with SARS-CoV-2 infection, per the judgment of the Investigator, within 14 days prior to Day -1, including but not limited to fever (temperature > 37.5 degrees Celsius [°C]), sore throat, new and persistent cough, shortness of breath, diarrhea, muscle aches, or loss of taste or smell Current enrollment in any other drug, biological, device, or clinical study, or treatment with an investigational drug or approved therapy for investigational use within 30 days prior to Day -1, or 5 half-lives, whichever is longer Any immunization or vaccination given within 10 days prior to administration of study treatment and for 10 days after administration of study treatment Mini mental state examination score of < 27 at Screening NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Aducanumab IV<br>Participants will receive a single weight-based dose of aducanumab via IV infusion on Day 1. | Biological: Aducanumab<br>* Administered as specified in the treatment arm.<br>* Other names: Aduhelm;|
| Experimental: Aducanumab SC<br>Participants will receive 2 fixed doses of aducanumab via SC injection on Days 1 and 15. | Biological: Aducanumab<br>* Administered as specified in the treatment arm.<br>* Other names: Aduhelm;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Aducanumab |  | Predose and at multiple time points post-dose up to Day 99 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, in the view of the investigator, places the participant at immediate risk of death (a life-threatening event), requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect or is a medically important event. | Up to Day 99 | 
| Number of Participants with Clinically Significant Abnormal Vital Sign Values |  | Up to Day 99 | 
| Number of Participants with Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Values |  | Day 1 and Day 99 | 
| Number of Participants with Clinically Significant Abnormal Laboratory Values |  | Up to Day 99 | 
| Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of Aducanumab |  | Predose and at multiple time points post-dose up to Day 99 | 
| Area Under the Concentration-Time Curve From Time 0 to 4 Weeks (AUC0-4wk) of Aducanumab |  | Predose and at multiple time points post-dose up to Day 28 | 
| Maximum Observed Concentration (Cmax) of Aducanumab |  | Predose and at multiple time points post-dose up to Day 99 | 
| Time to Reach Maximum Observed Concentration (Tmax) for Aducanumab Administered SC |  | Predose and at multiple time points post-dose up to Day 99 | 
| Elimination Half-Life (t1/2) of Aducanumab |  | Predose and at multiple time points post-dose up to Day 99 | 
| Volume of Distribution (Vd) or Apparent Volume of Distribution (V/F) of Aducanumab |  | Predose and at multiple time points post-dose up to Day 99 | 
| Clearance (CL) or Apparent Clearance (CL/F) of Aducanumab |  | Predose and at multiple time points post-dose up to Day 99 |